Turbine joins Multimodal AI-ready data collaboration to train Virtual Assays in immune biology
Read more

Publications

Target Discovery Through Mechanism-Enabled Simulations in the Virtual Lab 
Poster

Csilla Hegedüs, Katalin Szégner, László Mérő, Milán Sztilkovics, Zsolt Gyüre, Eszter Szarka, Iván Fekete,Maria Victoria Ruiz Perez, István Taisz, Imre Gáspár, Gábor Kovács, Kristóf Szalay, Dániel Veres, Krishna Bulusu

Minimizing the risk of late-stage failure in drug discovery for novel targets remains a central challenge in translational research. Conventional preclinical perturbation datasets lack mechanistic insight and context specificity. Turbine’s Virtual Biology capabilities which include the Simulated Cell™, Virtual Lab platform and Lab-in-the-Loop capabilities (Fig. 1.) offer rapid scalable access to simulations… read more

Virtual Cells: From Biological Complexity to Scalable R&D Advantage 
Whitepaper

Krishna C. Bulusu, Dániel Veres

Virtual Cell platforms are emerging as a transformative capability for drug discovery and development, enabling faster, more cost-efficient, and more productive R&D pipelines. By virtualizing biological experiments with AI-driven models, Virtual Cells allow researchers to simulate millions of perturbations in silico, far beyond what is feasible in the laboratory, while increasing the… read more

Assessing a Virtual Cell’s Utility 
TRAILWhitepaper

Bence Czakó, Gerold Csendes, Gema Sanz, Gábor Kovács, Kristóf Szalay, Bence Szalai

Perturbation modeling aims to find a model that can accurately predict the outcome of a perturbation on a given cell, such as a drug or CRISPRi intervention. Creating a massive amount of perturbation data is a challenging endeavor due to technical and financial constraints, which inhibit the progress of creating a biologically… read more

Integrating Virtual Cell Screening and Automated Validation to Accelerate Dual Payload ADC Design 
Poster

Dana Zemel, Murat Cem Köse, Róbert Sipos, Gábor Bereczki, Richárd Izrael, Gábor Glatz, Rawan Abukhairan, Csaba Szántai-Kis, Dóra Kállai, Jerzy Woźnicki, Meera Raja, Dániel Veres, Ákos Tarcsay

The ADC field is advancing rapidly, with 17 ADCs approved to date, including 13 by the U.S. FDA, and more than 300 candidates in clinical development. Among these, dual-payload conjugates and other next-generation designs are emerging to address limitations of current ADCs. read more

Benchmarking foundation cell models for post-perturbation RNA-seq prediction 
Poster

Gerold Csendes, Gema Sanz, Kristóf Szalay, Bence Szalai

Modeling cellular phenotypes is a fundamental challenge in computational systems biology. Accurately predicting cell fate can advance our understanding of both healthy and diseased states and facilitate the identification of novel therapeutic targets. Post-perturbation transcriptomics data are particularly suited for training computational models because the causal relationship between known perturbations and the… read more